A number of pre‐clinical models showed that PTEN‐deficient cancer cells are sensitive to inhibition of PI3K pathway, and this was particularly clear when p110β or AKT were selectively targeted (Chen et al, 2006; Jia et al, 2008; Wee et al, 2008; Vasudevan et al, 2009). This evidence concerns the gene PIK3CG and cancer.